Nurix therapeutics to present preclinical data from its novel btk degrader (nx-2127) and cbl-b inhibitor (nx-0255) programs at the american association for cancer research annual meeting

San francisco, march 08, 2022 (globe newswire) -- nurix therapeutics, inc.  (nasdaq: nrix), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its nx-2127 and detil-0255 clinical programs will be presented at the upcoming american association for cancer research (aacr) annual meeting, which is being held from april 8-13, 2022 in new orleans, la.
NRIX Ratings Summary
NRIX Quant Ranking